A5014399581- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Endometrial and Cervical Cancer Treatments
- Viral-associated cancers and disorders
- Endometriosis Research and Treatment
- Intestinal and Peritoneal Adhesions
- Gastrointestinal disorders and treatments
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- BRCA gene mutations in cancer
- Renal cell carcinoma treatment
- Enhanced Recovery After Surgery
- Reproductive Biology and Fertility
- Ovarian function and disorders
- Testicular diseases and treatments
- Cancer, Lipids, and Metabolism
Memorial Sloan Kettering Cancer Center
2005-2011
Weatherford College
2006-2007
Cleveland Clinic
2006
Abstract BACKGROUND The benefit of cytoreductive surgery for patients with recurrent epithelial ovarian cancer has not been defined clearly. objective this study was to identify prognostic factors survival in who underwent secondary cytoreduction recurrent, platinum‐sensitive and establish generally applicable guidelines selection criteria. METHODS authors reviewed all from 1987 2001. Potential were evaluated univariate multivariate analyses. RESULTS In total, 157 cytoreduction, 153 those...
Abstract Objective. To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer. Methods. An institutional study was conducted from July 2002 2003 prospectively identify pts who underwent an procedure palliate the symptoms of advanced This report focuses with Procedures performed upper lower gastrointestinal (GI) endoscope were considered “endoscopic.” All other cases classified...
The objective of this study was to determine the impact malignant pleural effusions on survival in patients with optimally debulked, advanced epithelial ovarian carcinoma.The authors conducted a retrospective review all carcinoma who underwent optimal primary cytoreduction at their institution between January 1987 and August 2000. Survival rates were compared debulked Stage IIIC IV (according International Federation Gynecology Obstetrics [FIGO] staging system) based cytology-proven...
What constitutes “optimal” cytoreduction for women operated on ovarian cancer remains uncertain. A majority of studies have employed a cutoff 1–2 cm to define optimal cytoreduction. Recent suggest that removing all gross disease promotes disease-free survival compared the current Gynecologic Oncology Group threshold 1 or less residual disease. This prospective database analysis reviewed records 465 patients with stage IIIC epithelial carcinoma (EOC) who had cytoreductive surgery in years...
5523 Background: Nomograms have been shown to be superior traditional staging systems for predicting an individual's probability of long-term survival. Our objective was develop a nomogram based on established prognostic factors predict the 5-year disease-specific survival (DSS) after primary surgery patients with epithelial ovarian cancer (EOC) and compare its predictive accuracy currently used FIGO system. Methods: We identified all pts EOC who had their staging/cytoreductive at our...
Second-look surgery (SLS) is the most reliable means available for assessing ovarian cancer after primary treatment, because it can detect residual in patients who have completed a course of chemotherapy and are complete clinical remission. The investigators undertook retrospective chart review with epithelial had positive findings on SLS. All 262 achieved remission therapy. A majority initially presented FIGO stage IIIC disease, grade 3 tumors, serous histology, ascites. Nearly two thirds...
5058 Background: Nomograms have been developed for numerous malignancies to predict a specific individual’s probability of long-term survival based on known prognostic factors. To date, no prediction model has patients with ovarian cancer. The objective this study was develop nomogram the 4-year after primary cytoreductive surgery bulky stage IIIC carcinoma. Methods: Nomogram predictor variables included age, tumor grade, histologic type, preoperative platelet count, presence or absence...